Home > Insider Trading > Filing (0000899243-20-032703)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1403752	Zymeworks Inc.	ZYME	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1563992	Diana Hausman	C/O Zymeworks Inc. 1385 West 8Th Avenue, Suite 540 Vancouver A1 V6H 3V9	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2020-12-01	4,122	$9.82	7,840	No	4	M	Direct
Common Shares	Acquisiton	2020-12-01	14,145	$11.84	21,985	No	4	M	Direct
Common Shares	Disposition	2020-12-01	18,267	$55.19	3,718	No	4	S	Direct
Common Shares	Acquisiton	2020-12-02	127	$9.82	3,845	No	4	M	Direct
Common Shares	Acquisiton	2020-12-02	574	$11.84	4,419	No	4	M	Direct
Common Shares	Disposition	2020-12-02	701	$55.01	3,718	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2020-12-01	4,122	$0.00	4,122	$9.82
Common Shares	Stock Option (Right to Buy)	Disposition	2020-12-01	14,145	$0.00	14,145	$11.84
Common Shares	Stock Option (Right to Buy)	Disposition	2020-12-02	127	$0.00	127	$9.82
Common Shares	Stock Option (Right to Buy)	Disposition	2020-12-02	574	$0.00	574	$11.84

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,878	2018-06-12	2027-06-12	No	4	M	Direct
50,855	2019-03-19	2028-03-18	No	4	M	Direct
70,751	2018-06-12	2027-06-12	No	4	M	Direct
50,281	2019-03-19	2028-03-18	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	2,000	Indirect	Held by spouse

Footnotes

Pursuant to a 10b5-1 plan.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.67, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.05, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 2, 2020 at each separate price.
Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date.